Uganda established a domestic Viral Hemorrhagic Fever (VHF) testing capacity in 2010 in response to the increasing occurrence of filovirus outbreaks. In July 2018, the neighboring Democratic Republic of Congo (DRC) experienced its 10th Ebola Virus Disease (EVD) outbreak and for the duration of the outbreak, the Ugandan Ministry of Health (MOH) initiated a national EVD preparedness stance. Almost one year later, on 10th June 2019, three family members who had contracted EVD in the DRC crossed into Uganda to seek medical treatment. Samples were collected from all the suspected cases using internationally established biosafety protocols and submitted for VHF diagnostic testing at Uganda Virus Research Institute. All samples were initially tested by RT-PCR for ebolaviruses, marburgviruses, Rift Valley fever (RVF) virus and Crimean-Congo hemorrhagic fever (CCHF) virus. Four people were identified as being positive for Zaire ebolavirus, marking the first report of Zaire ebolavirus in Uganda. In-country Next Generation Sequencing (NGS) and phylogenetic analysis was performed for the first time in Uganda, confirming the outbreak as imported from DRC at two different time point from different clades. This rapid response by the MoH, UVRI and partners led to the control of the outbreak and prevention of secondary virus transmission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896669 | PMC |
| http://dx.doi.org/10.1371/journal.pntd.0010205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
PLoS Pathog
December 2024
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP).
View Article and Find Full Text PDFEbola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination.
N Engl J Med
December 2024
From the Institut National de Recherche Biomédicale and Faculté de Médecine, Université de Kinshasa (J.-J.M., P.M.-K., S.M., S.A.-M.), and the Ministry of Public Health (S.H.B.M., N.T., E.M.M.) - both in Kinshasa, Democratic Republic of Congo; the Nuffield Department of Population Health, University of Oxford, Oxford (H.P., R.P.), and the London School of Hygiene and Tropical Medicine, London (C.H.R., M.M.) - both in the United Kingdom; University of Florida, Gainesville (I.M.L.); and the World Health Organization, Geneva (A.D., A.T., G.E., P.-S.G., X.R.B., M.N.K.Y., A.S.G., I.-S.F., P.S., M.J.R., A.M.H.-R.).
Background: At the beginning of the 2018-2020 outbreak of Ebola virus disease (EVD) in eastern Democratic Republic of Congo (DRC), no vaccine had been licensed. However, cluster-randomized evidence from Guinea in 2015 had indicated that ring vaccination around new cases (targeting contacts and contacts-of-contacts) with the use of single-dose live-replicating rVSV-ZEBOV-GP vaccine reduced EVD rates starting 10 days after vaccination. Thus, ring vaccination was added to the standard control measures for that outbreak.
View Article and Find Full Text PDFInhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine.
Antiviral Res
January 2025
Department of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus-von-Liebig-Weg 11, 37077, Göttingen, Germany; Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, 37077, Göttingen, Germany. Electronic address:
Article Synopsis
- - RNA viruses like influenza and coronaviruses pose significant health threats, often lacking effective vaccines or treatments, while others like filo- and henipaviruses have high mortality rates despite limited outbreaks.
- - The antiviral drug 4'-Fluorouridine (4'-FlU) inhibits RNA virus replication by targeting the RNA-dependent RNA polymerase, but its effectiveness varies across different viruses, necessitating strategies to improve its potency.
- - Researchers found that inhibiting dihydroorotate dehydrogenase (DHODH) enhances the antiviral effects of 4'-FlU against several RNA viruses, including in models of infection, potentially by depleting uridine, which boosts 4'-FlU's incorporation into viral
Hepatic and pulmonary macrophage activity in a mucosal challenge model of Ebola virus disease.
Front Immunol
December 2024
Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States.
Background: The inflammatory macrophage response contributes to severe Ebola virus disease, with liver and lung injury in humans.
Objective: We sought to further define the activation status of hepatic and pulmonary macrophage populations in Ebola virus disease.
Methods: We compared liver and lung tissue from terminal Ebola virus (EBOV)-infected and uninfected control cynomolgus macaques challenged via the conjunctival route.
Quantification of heterogeneity in human CD8 T cell responses to vaccine antigens: an HLA-guided perspective.
Front Immunol
December 2024
Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Article Synopsis
- * The authors suggest new metrics to measure how well vaccines stimulate CD8 T cells and identify key viral parts that trigger immune response, considering genetic differences among people and viral changes.
- * The proposed methods were tested successfully using proteins from the Ebola virus and SARS-CoV-2 vaccines, showing the effectiveness of their approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!